Volume

Targeting MYC-driven lymphoma: lessons learned and future directions

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Cancer stem cells in drug resistance: an introduction to the e-book covering the special issue on the “Cancer Stem Cells and Drug Resistance”

miR-16-5p enhances sensitivity to RG7388 through targeting <i>PPM1D</i> expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Importance of <i>ROS1</i> gene fusions in non-small cell lung cancer

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

Interaction of pregnane X receptor with hypoxia-inducible factor-1 regulates chemoresistance of prostate cancer cells

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/